Hemophagocytic  ||| S:0 E:15 ||| JJ
lymphohistiocytosis  ||| S:15 E:35 ||| NNS
( ||| S:35 E:36 ||| -LRB-
HLH ||| S:36 E:39 ||| NNP
)  ||| S:39 E:41 ||| -RRB-
in  ||| S:41 E:44 ||| IN
a  ||| S:44 E:46 ||| DT
25-year-old  ||| S:46 E:58 ||| JJ
presenting  ||| S:58 E:69 ||| NN
with  ||| S:69 E:74 ||| IN
multisystem  ||| S:74 E:86 ||| FW
organ  ||| S:86 E:92 ||| FW
failure  ||| S:92 E:100 ||| FW
Hemophagocytic  ||| S:100 E:115 ||| FW
lymphohistiocytosis  ||| S:115 E:135 ||| FW
( ||| S:135 E:136 ||| -LRB-
HLH ||| S:136 E:139 ||| NNP
)  ||| S:139 E:141 ||| -RRB-
is  ||| S:141 E:144 ||| VBZ
a  ||| S:144 E:146 ||| DT
rare  ||| S:146 E:151 ||| JJ
syndrome  ||| S:151 E:160 ||| NN
of  ||| S:160 E:163 ||| IN
extreme  ||| S:163 E:171 ||| JJ
inflammation  ||| S:171 E:184 ||| NNS
caused  ||| S:184 E:191 ||| VBN
by  ||| S:191 E:194 ||| IN
pathologic  ||| S:194 E:205 ||| JJ
activation  ||| S:205 E:216 ||| NN
of  ||| S:216 E:219 ||| IN
the  ||| S:219 E:223 ||| DT
immune  ||| S:223 E:230 ||| JJ
system ||| S:230 E:236 ||| NN
.  ||| S:236 E:238 ||| .
Diagnosis  ||| S:238 E:248 ||| NN
of  ||| S:248 E:251 ||| IN
HLH  ||| S:251 E:255 ||| NNP
is  ||| S:255 E:258 ||| VBZ
challenging  ||| S:258 E:270 ||| VBG
as  ||| S:270 E:273 ||| IN
the  ||| S:273 E:277 ||| DT
clinical  ||| S:277 E:286 ||| JJ
presentation  ||| S:286 E:299 ||| NN
is  ||| S:299 E:302 ||| VBZ
similar  ||| S:302 E:310 ||| JJ
to  ||| S:310 E:313 ||| TO
common  ||| S:313 E:320 ||| JJ
medical  ||| S:320 E:328 ||| JJ
entities  ||| S:328 E:337 ||| NNS
such  ||| S:337 E:342 ||| JJ
as  ||| S:342 E:345 ||| IN
sepsis ||| S:345 E:351 ||| NN
.  ||| S:351 E:353 ||| .
When  ||| S:353 E:358 ||| WRB
a  ||| S:358 E:360 ||| DT
source  ||| S:360 E:367 ||| NN
of  ||| S:367 E:370 ||| IN
the  ||| S:370 E:374 ||| DT
extreme  ||| S:374 E:382 ||| JJ
inflammation  ||| S:382 E:395 ||| NN
is  ||| S:395 E:398 ||| VBZ
not  ||| S:398 E:402 ||| RB
found ||| S:402 E:407 ||| VBN
,  ||| S:407 E:409 ||| ,
HLH  ||| S:409 E:413 ||| NNP
should  ||| S:413 E:420 ||| MD
be  ||| S:420 E:423 ||| VB
considered  ||| S:423 E:434 ||| VBN
in  ||| S:434 E:437 ||| IN
the  ||| S:437 E:441 ||| DT
differential  ||| S:441 E:454 ||| JJ
diagnosis ||| S:454 E:463 ||| NN
.  ||| S:463 E:465 ||| .
In  ||| S:465 E:468 ||| IN
HLH ||| S:468 E:471 ||| NNP
,  ||| S:471 E:473 ||| ,
inflammatory  ||| S:473 E:486 ||| JJ
markers  ||| S:486 E:494 ||| JJ
such  ||| S:494 E:499 ||| JJ
as  ||| S:499 E:502 ||| IN
soluble  ||| S:502 E:510 ||| JJ
CD25  ||| S:510 E:515 ||| NN
and  ||| S:515 E:519 ||| CC
ferritin  ||| S:519 E:528 ||| JJ
levels  ||| S:528 E:535 ||| NNS
are  ||| S:535 E:539 ||| VBP
elevated ||| S:539 E:547 ||| VBN
.  ||| S:547 E:549 ||| .
Ferritin  ||| S:549 E:558 ||| JJ
assay  ||| S:558 E:564 ||| NN
is  ||| S:564 E:567 ||| VBZ
widely  ||| S:567 E:574 ||| RB
available  ||| S:574 E:584 ||| JJ
at  ||| S:584 E:587 ||| IN
most  ||| S:587 E:592 ||| JJS
institutions ||| S:592 E:604 ||| NNS
;  ||| S:604 E:606 ||| :
a  ||| S:606 E:608 ||| DT
level  ||| S:608 E:614 ||| NN
greater  ||| S:614 E:622 ||| JJR
than  ||| S:622 E:627 ||| IN
10,000  ||| S:627 E:634 ||| CD
is  ||| S:634 E:637 ||| VBZ
highly  ||| S:637 E:644 ||| RB
suggestive  ||| S:644 E:655 ||| VBN
of  ||| S:655 E:658 ||| IN
HLH.2  ||| S:658 E:664 ||| CD
Delayed  ||| S:664 E:672 ||| JJ
diagnosis  ||| S:672 E:682 ||| NN
and  ||| S:682 E:686 ||| CC
failure  ||| S:686 E:694 ||| NN
to  ||| S:694 E:697 ||| TO
initiate  ||| S:697 E:706 ||| VB
cytotoxic  ||| S:706 E:716 ||| JJ
chemotherapy  ||| S:716 E:729 ||| NN
will  ||| S:729 E:734 ||| MD
result  ||| S:734 E:741 ||| VB
in  ||| S:741 E:744 ||| IN
a  ||| S:744 E:746 ||| DT
fatal  ||| S:746 E:752 ||| JJ
outcome ||| S:752 E:759 ||| NN
.  ||| S:759 E:761 ||| .
